(PRWEB) June 23, 2012
SituGen belongs to fast growing field of regeneration medicine based on using Cord Blood Stem Cells. It is a unique device for stem cells collection, with a user-interface design optimizes the extraction of Stem Cells.
The problem of the existing method of cord blood collection is the relatively slow process, resulting in cord blood quickly coagulating and therefore be difficult to be fully extracted. The limited volume of blood collected from the umbilical cord substantially limits the ability of fully exploit its potential. Currently the average volume of blood collected restricts the therapeutic use of cord blood stem cells to patients weighing an average of only 77Lbs., which eliminates the majority of adult patients. SituGen enhances cord blood collections over 81% more stem cells, making the rapeutic use of cord blood stem cells available for Adults.
This is a significant breakthrough as stem cells are widely tested in clinical trials for treating Alzheimer's disease, Parkinson's disease, Strokes, Muscular Dystrophy, Paralysis, Cerebral Palsy, Diabetes Mellitus, heart & lung diseases and others.
SituGen, provides richer units of stem cells for use in hematology and in regenerative medicine.
HOW IT WORKS
SituGen's solution is a disposable comprehensive all-inclusive kit for cord blood stem cells collection. It is a needle free "open" collection system in a complete Closed & Sterile environment.
The SituGen's kit includes the collection device and all the peripheral accessories 2 clamps ruler scissors, a syringe with chlorhexidine solution, preps for cleaning the Umbilical cord and blood collection bags. The three stages of collection are:
1. Inserting the cord into the device.
2. Disinfect it.
3. Collecting the Cord Blood in blood bags.
SituGen is active in R&D in the fields of Stem Cells, Cord Blood and Placenta – Umbilicus Coagulation. The company founded around its recent development of the novel efficient and low cost SituGen device for a maximum-volume extraction of umbilical cord blood for the purpose of stem cells harvesting. SituGen's R&D team has been currently running other projects, which focus on further study of cord blood coagulation within the Placenta/Umbilicus system.